President Donald Trump’s nominee to lead the U.S. Food and Drug Administration, Dr. Heidi Overton, faces questions from senators on vaccines, mifepristone and the future direction of the agency.
The Senate Health, Education, Labor and Pensions Committee is holding Overton’s confirmation hearing on September 24, 2026. The hearing comes as the FDA works to rebuild its workforce after major staff losses.
Quick Fact
| Detail | Information |
|---|---|
| What happened | Heidi Overton faces a U.S. Senate confirmation hearing for FDA commissioner. |
| Where | U.S. Senate, Washington, D.C. |
| When | September 24, 2026 |
| Nominee | Dr. Heidi Overton |
| Nominated by | President Donald Trump |
| Key issues | Vaccines, mifepristone, FDA policy and agency leadership |
| Committee | Senate Health, Education, Labor and Pensions Committee |
| Why it matters | The FDA oversees medicines, vaccines, medical devices and other public health products. |
Senate Hearing Focuses on FDA Nominee
Senators are expected to question Overton about her plans for the FDA and her views on several major health issues.
Overton serves as deputy director of the White House Domestic Policy Council. She previously worked at the America First Policy Institute. Trump nominated her in August to replace former FDA Commissioner Marty Makary. cials have since started rebuilding the workforce and received authorization to hire about 2,200 people.
Vaccines Expected to Draw Questions
Vaccines are likely to receive significant attention during the hearing.
Overton appeared with Trump when he announced changes to federal childhood vaccine recommendations in August. The administration also proposed separating the combined measles, mumps and rubella vaccine into three separate shots.
Senator Bill Cassidy, a Republican from Louisiana and chairman of the Senate health committee, has questioned parts of the administration’s vaccine policy. His views could make vaccine policy an important part of Overton’s confirmation hearing.
Abortion Pill Policy Also Under Review
Overton’s views on abortion are another major issue for senators.
She previously described the Supreme Court’s 2022 decision to overturn Roe v. Wade as a victory for the anti abortion movement. Her past policy work on abortion has also drawn attention from abortion rights groups.
If confirmed, Overton would take charge of the FDA while the agency reviews its policies involving mifepristone, a medication used for abortion and miscarriage management. Reuters reported that the FDA faces an October 7 deadline to update a federal court on its review.
FDA Faces Broader Challenges
The next FDA commissioner will oversee an agency dealing with major organizational changes.
The FDA regulates medicines, vaccines, medical devices and other products that affect public health. The agency has also faced questions about scientific decision making and political pressure.
HHS announced several new senior FDA appointments earlier this month. The changes include new leadership for drug evaluation, biologics and technology policy.
Overton would therefore take the FDA leadership role during a period of significant change.
Nicole Saphier Nomination
The Senate health committee is also considering Dr. Nicole Saphier for U.S. surgeon general.
Saphier appeared before the committee earlier in September. Senators questioned her about vaccines and the disputed claim linking vaccines to autism. She said vaccines do not cause autism, according to reporting on the hearing.
The committee is scheduled to consider her nomination alongside several other Trump administration nominees.
Next Steps for Overton Nomination
Overton’s nomination will continue through the Senate confirmation process after the committee hearing.
The committee must decide whether to advance the nomination. The full Senate would then consider whether to confirm her as FDA commissioner.
Heidi Overton’s confirmation hearing puts several major health policy questions before the Senate.
Vaccines, abortion medication, FDA staffing and the agency’s independence are likely to remain important issues as lawmakers consider her nomination.
